Is Eli Lilly Overpaying for Loxo Oncology?

Is Eli Lilly Overpaying for Loxo Oncology?

Source: 
Motley Fool
snippet: 

Eli Lilly (NYSE:LLY) shares finished Monday on a slightly positive note after the company announced an agreement to acquire Loxo Oncology (NASDAQ:LOXO) for $8 billion in cash. That's not an outrageous sum to pay for a biotech that's already earned its first FDA approval, but Lilly might have more trouble selling Loxo's recently acquired drug than imagined.